Kanawha Capital Management LLC Buys 148 Shares of Johnson & Johnson $JNJ

Kanawha Capital Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 0.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,086 shares of the company’s stock after purchasing an additional 148 shares during the quarter. Johnson & Johnson makes up approximately 1.7% of Kanawha Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Kanawha Capital Management LLC’s holdings in Johnson & Johnson were worth $22,926,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.6%

JNJ opened at $193.27 on Friday. The company’s 50 day moving average is $180.49 and its 200-day moving average is $164.86. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a market cap of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion for the quarter. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on JNJ shares. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Bank of America upped their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.59.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.